Brand Name: Pulmozyme
Generic: dornase alfa
Type: monoclonal antibody
Year Accepted/Phase: 1993

Mechanism:

Dornase alfa breaks down the DNA in the mucus of the lungs, reducing its viscosity and making it easier to clear from the airways. This improves airflow and reduces risk of infections.

Chemical Structure: N/A

Indication:

Pulmozyme is indicated for use in patients with Cystic Fibrosis (CF) to improve lung function and reduce the frequency of respiratory exacerbations.

Clinical trials:

Phase III Trials

Purpose: Evaluate the efficacy and safety of Pulmozyme in patients with CF.
Dates: Trials conducted in the 1980s.
Results: Pulmozyme was shown to improve lung function, reduce the frequency of respiratory exacerbations, and improve quality of life in patients with CF. It also reduced the viscosity of sputum, making it easier to clear from the lungs.
Impact: These trials supported the approval of Pulmozyme for the treatment of CF.

Long-Term Studies

Purpose: Assess the long-term safety and efficacy of Pulmozyme in patients with CF.
Dates: Ongoing since the initial approval.
Results: Long-term studies have confirmed the continued benefits of Pulmozyme in improving lung function and reducing respiratory exacerbations in patients with CF. The safety profile of Pulmozyme has also remained favorable over extended periods of use.
Impact: These studies have provided valuable data on the long-term use of Pulmozyme and have supported its continued use as a standard treatment for CF.